Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -54.15% is 1014% below its 5-year average of -4.86%, near the low end of its 5-year range (-64.64%–59.08%).
As of the fiscal period ended Friday, July 31, 2026. 89.67% below its 12-month average of -28.55%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q1 FY2027 (2026-07-31): -54.15%.
RETURN ON EQUITY (ROE)
-54.15%
RETURN ON EQUITY (ROE) AVG TTM
-28.55%
RETURN ON EQUITY (ROE) AVG 3Y
4.30%
RETURN ON EQUITY (ROE) AVG 5Y
-4.86%
RETURN ON EQUITY (ROE) AVG 10Y
-38.96%
RETURN ON EQUITY (ROE) AVG 15Y
-56.07%
RETURN ON EQUITY (ROE) AVG 20Y
-73.83%
CURRENT VS TTM AVG
-89.67%
CURRENT VS 3Y AVG
-1358.99%
CURRENT VS 5Y AVG
-1013.54%
CURRENT VS 10Y AVG
-39.00%
CURRENT VS 15Y AVG
+3.43%
CURRENT VS 20Y AVG
+26.65%
SECTOR MEDIAN · HEALTHCARE
-40.89%
median of 684 covered companies
CURRENT VS SECTOR MEDIAN
-32.43%
vs the sector median at left
PharmaCyte Biotech, Inc.
Market Cap
$4.60M
Return on Equity (ROE)
-54.15%
TTM Avg
-28.55%
3Y Avg
4.30%
5Y Avg
-4.86%
Market Cap
$4.43M
Return on Equity (ROE)
-424.89%
TTM Avg
-156.14%
3Y Avg
-97.37%
5Y Avg
-86.32%
Market Cap
$4.52M
Return on Equity (ROE)
-239.95%
TTM Avg
-454.28%
3Y Avg
-297.70%
5Y Avg
-194.53%
Market Cap
$4.24M
Return on Equity (ROE)
-184.04%
TTM Avg
9542.92%
3Y Avg
4740.03%
5Y Avg
3155.09%
Market Cap
$4.63M
Return on Equity (ROE)
-385.27%
TTM Avg
175.03%
3Y Avg
3.40%
5Y Avg
-11.76%
Market Cap
$4.64M
Return on Equity (ROE)
-30.74%
TTM Avg
235.96%
3Y Avg
-836.91%
5Y Avg
-570.34%
Market Cap
$4.15M
Return on Equity (ROE)
N/A
TTM Avg
-201.28%
3Y Avg
-1309.54%
5Y Avg
-838.52%
Market Cap
$4.01M
Return on Equity (ROE)
-310.33%
TTM Avg
-204.84%
3Y Avg
-115.20%
5Y Avg
-69.88%
Market Cap
$4.07M
Return on Equity (ROE)
N/A
TTM Avg
-470.92%
3Y Avg
-382.96%
5Y Avg
-276.61%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| PharmaCyte Biotech, Inc. (PMCB) | $4.60M | -54.15% | -28.55% | 4.30% | -4.86% |
| CollPlant Biotechnologies Ltd. (CLGN)vs › | $4.43M | -424.89% | -156.14% | -97.37% | -86.32% |
| Dermata Therapeutics, Inc. (DRMA)vs › | $4.52M | -239.95% | -454.28% | -297.70% | -194.53% |
| 20/20 Biolabs Inc. (AIDX)vs › | $4.24M | -184.04% | 9542.92% | 4740.03% | 3155.09% |
| CalciMedica, Inc. (CALC)vs › | $4.63M | -385.27% | 175.03% | 3.40% | -11.76% |
| Bio Green Med Solution, Inc. (BGMS)vs › | $4.64M | -30.74% | 235.96% | -836.91% | -570.34% |
| GRI Bio, Inc. (GRI)vs › | $4.15M | N/A | -201.28% | -1309.54% | -838.52% |
| 60 Degrees Pharmaceuticals, Inc. (SXTP)vs › | $4.01M | -310.33% | -204.84% | -115.20% | -69.88% |
| Processa Pharmaceuticals, Inc. (PCSA)vs › | $4.07M | N/A | -470.92% | -382.96% | -276.61% |
| Lexaria Bioscience Corp. (LEXX)vs › | $4.78M | -163.18% | -235.11% | -195.15% | -161.13% |
ROE
-54.2%
ROA
-44.0%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-07-31 | -54.15% |
| 2026-04-30 | -58.34% |
| 2026-01-31 | -8.33% |
| 2025-10-31 | -19.35% |
| 2025-07-31 | -2.58% |
| 2025-04-30 | 59.08% |
| 2025-01-31 | 50.32% |
| 2024-10-31 | 52.19% |
| 2024-07-31 | 50.79% |
| 2024-04-30 | 0.84% |
| 2024-01-31 | -2.33% |
| 2023-10-31 | -2.21% |
| 2023-07-31 | -10.01% |
| 2023-04-30 | -5.94% |
| 2023-01-31 | -7.28% |
| 2022-10-31 | -6.98% |
| 2022-07-31 | -5.51% |
| 2022-04-30 | -4.71% |
| 2022-01-31 | -4.13% |
| 2021-10-31 | -4.04% |
| 2021-07-31 | -64.64% |
| 2021-04-30 | -53.17% |
| 2021-01-31 | -43.89% |
| 2020-10-31 | -41.80% |
| 2020-07-31 | -57.27% |
| 2020-04-30 | -75.20% |
| 2020-01-31 | -97.59% |
| 2019-10-31 | -88.58% |
| 2019-07-31 | -79.73% |
| 2019-04-30 | -80.71% |
| 2019-01-31 | -78.72% |
| 2018-10-31 | -103.22% |
| 2018-07-31 | -102.54% |
| 2018-04-30 | -118.38% |
| 2018-01-31 | -114.57% |
| 2017-10-31 | -80.83% |
| 2017-07-31 | -58.90% |
| 2017-04-30 | -54.95% |
| 2017-01-31 | -62.68% |
| 2016-10-31 | -78.30% |
| 2016-07-31 | -78.97% |
| 2016-04-30 | -92.96% |
| 2016-01-31 | -125.28% |
| 2015-10-31 | -127.36% |
| 2015-07-31 | -155.03% |
| 2015-04-30 | -139.57% |
| 2015-01-31 | -377.36% |
| 2014-10-31 | -353.76% |
| 2014-07-31 | -308.83% |
| 2014-04-30 | -304.77% |
| 2014-01-31 | -214.36% |
| 2013-10-31 | -306.07% |
| 2013-07-31 | -239.71% |
| 2010-01-31 | -517.53% |
| 2009-10-31 | -214.98% |
| 2009-07-31 | -198.66% |
| 2009-04-30 | -192.15% |
| 2009-01-31 | -51.40% |
| 2008-10-31 | -46.52% |
| 2008-07-31 | -48.84% |
| 2008-04-30 | -51.01% |
| 2008-01-31 | -81.27% |
| 2007-10-31 | -106.12% |
| 2007-07-31 | -77.24% |
| 2007-04-30 | -84.32% |
| 2007-01-31 | -252.98% |
| 2006-10-31 | -231.93% |
| 2006-07-31 | -248.42% |
| 2006-04-30 | -199.68% |
| 2004-01-31 | -10.82% |
| 2003-10-31 | -6.54% |
